Effective October 2, 2018, physicians will be required to consult the CURES database (California’s Prescription Drug Monitoring Database [PDMD]) prior to prescribing Schedule II, III, or IV controlled substances to a patient for the first time and at least once every four months thereafter if that substance remains part of the patient’s treatment. The California Department of Justice (DOJ) certified that CURES was functional on April 2, 2018, and per Senate Bill 482 passed in 2016, the mandate to consult CURES will go into effect 6 months after that date. There are exceptions to this duty to consult, including instances of inaccurate information or periods of non-functionality of CURES, prescriptions to only be used on facility premises, patients in hospice care, and prescriptions for short-term surgical recovery. For more information on CURES and the duty to consult, ACCMA/CMA members can access this free CMA guide. Others may consult the DOJ CURES user guide at https://oag.ca.gov/sites/all/files/agweb/pdfs/pdmp/cures-2.0-user-guide.pdf.